Severe gastrointestinal inflammation could occur in 2 percent to 3 percent of patients who receive Carvykti, the FDA has informed patients and doctors.
The drugmaker said it plans to submit a regulatory application for DB-OTO to the FDA later this year, pending discussions with the agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback